Clinical Trial Update: Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating intrathecal rituximab in patients with recurrent central nervous system lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Central Nervous System Lymphoma

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Brain and Central Nervous System Tumors, Lymphoma | Phase 1 | Status: COMPLETED